EN

Your shopping cart

Amount

Total (VAT incl.)

VAT (21%)
Total
You have not added any reports to the cart yet.
Request reports
If you prefer to place your order via e-mail
contact us at: digital@azierta.com

Events and news

Blog
Home > Blog > Regulatory Affairs

How to proceed with an active ingredient that can be effective in the management of SARS-CoV-2 respiratory infection

Although numerous clinical trials are underway, there is currently no evidence from controlled clinical trials to recommend a specific treatment for SARS-CoV-2. Therefore, the Spanish Agency for Medicines and Healthcare Products (AEMPS) is continuously monitoring with experts from European agencies, the EMA and other agencies outside the EU all data related to the use of medicines for the treatment or prophylaxis of respiratory infection by SARS-CoV-2.

In this context, and even if other options exist, it is recommended to prioritize the possibility of conducting clinical studies so that, while offering a plausible treatment alternative, they generate useful knowledge since, to date, there are only partial, preliminary, sometimes only in vitro, or even contradictory data on the efficacy of one or another product.

The priority objective is to be able to collect and process in the best way all the information that is being generated, to be able to monitor continuously all this information of the uses of the medicines that are being used as treatment.

In addition, the review of the stock and supplies is becoming necessary to avoid current and future shortages both for this pathology and for other indications in the case of already authorised drugs. The importance of reporting all suspected adverse reactions to the corresponding Autonomous Centre for pharmacovigilance or through the electronic form available at www.notificaram.com is also recalled.

At Azierta, we have a team of multidisciplinary experts ready to help you in any of these stages, speeding up the process as much as possible.  Contact us. 

You can find more information at:

https://www.aemps.gob.es/la-aemps/ultima-informacion-de-la-aemps-acerca-del-covid%e2%80%9119/tratamientos-disponibles-para-el-manejo-de-la-infeccion-respiratoria-por-sars-cov-2/

Back

Related posts

Accessing the European Pharma Market: becoming a MAH through...

Positioned as the second largest pharmaceutical market in the world and showing a steady and extensive growth pattern, Europe’s...

Read more

Biotechnology: Incentives of the Advanced Medicinal Products...

What are Advanced Therapies? Advanced-therapy medicines are medicines that are made from genes and cells. They may offer...

Read more

Leading innovation in pharma & health

100 professionals

Over 100 professionals

500 clients

Over 500 clients

9 year experience

9 years of experience

Innovation

Leading innovation

Client oriented

100% client oriented

We are at your complete disposal for any inquiry

Thank you for getting in touch! We will contact you as soon as possible to help you out
There has been an error while submitting your form, please try again, or call us at 912 77 10 76
Schedule appointment

Schedule a video call with our field experts

schedule
We use "cookies" to improve your experience on our site. Cookies enable us to tailor messages and display ads to your interests. They also help us understand how our site is being used. By continuing to use our site you consent to use our cookies.